Mn2+-ZnSe/ZnS@SiO₂ Nanoparticles for Turn-on Luminescence Thiol Detection

Use of metal nanoparticles for preconcentration and analysis of biological thiols

Metal nanoparticles (NPs) exhibit several unique physicochemical properties, including redox activity, surface plasmon resonance, ability to quench fluorescence, biocompatibility, or a high surface-to-volume ratio. They are being increasingly used in analysis and preconcentration of thiol containing compounds, because they are able to spontaneously form a stable Au/Ag/Cu-S dative bond. They thus find wide application in environmental and particularly in medical science, especially in the analysis of biological thiols, the endogenous compounds that play a significant role in many biological systems. In this review article, we provide an overview of various types of NPs that have been applied in analysis and preconcentration of biological thiols, mainly in human biological fluids. We first discuss shortly the types of NPs and their synthesis, properties, and their ability to interact with thiol compounds. Then we outline the sample preconcentration and analysis methods that were used for this purpose with special emphasis on optical, electrochemical, and separation techniques.

Zn-based physiometacomposite nanoparticles: distribution, tolerance, imaging, and antiviral and anticancer activity

The aim of this study was to investigate the distribution, tolerance, and anticancer and antiviral activity of Zn-based physiometacomposites (PMCs). Manganese, iron, nickel and cobalt-doped ZnO, ZnS or ZnSe were synthesized. Cell uptake, distribution into 3D culture and mice, and biochemical and chemotherapeutic activity were studied by fluorescence/bioluminescence, confocal microscopy, flow cytometry, viability, antitumor and virus titer assays. Luminescence and inductively coupled plasma mass spectrometry analysis showed that nanoparticle distribution was liver >spleen >kidney >lung >brain, without tissue or blood pathology. Photophysical characterization as ex vivo tissue probes and LL37 peptide, antisense oligomer or aptamer delivery targeting RAS/Ras binding domain (RBD) was investigated. Treatment at 25 μg/ml for 48 h showed ≥98-99% cell viability, 3D organoid uptake, 3-log inhibition of β-Galactosidase and porcine reproductive respiratory virus infection. Data support the preclinical development of PMCs for imaging and delivery targeting cancer and infectious disease.